Cargando…
Post‐treatment clinical course following botulinum toxin injection therapy for adductor spasmodic dysphonia: Analysis of data from a placebo‐controlled, randomized, double‐blinded clinical trial in Japan
OBJECTIVE: Botulinum toxin (BT) therapy is a first‐line treatment for spasmodic dysphonia (SD). However, a detailed chronological course and clinical factors that affect the therapeutic effect have been vague. In this study, we analyzed the data from our placebo‐controlled, randomized, double‐blinde...
Autores principales: | Hirose, Kahori, Asano, Kento, Sakaguchi, Masahiko, Nagao, Asuka, Nakahira, Maya, Doi, Nao, Kobayashi, Taisuke, Hyodo, Masamitsu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513418/ https://www.ncbi.nlm.nih.gov/pubmed/34667852 http://dx.doi.org/10.1002/lio2.669 |
Ejemplares similares
-
Botulinum Toxin Therapy for Spasmodic Dysphonia in Japan: The History and an Update
por: Hyodo, Masamitsu, et al.
Publicado: (2022) -
Validity of intraoperative voice monitoring undergoing type 2 thyroplasty with titanium bridges for adductor spasmodic dysphonia
por: Sanuki, Tetsuji, et al.
Publicado: (2022) -
Botulinum Toxin Therapy: A Series of Clinical Studies on Patients with Spasmodic Dysphonia in Japan
por: Hyodo, Masamitsu, et al.
Publicado: (2021) -
Optimizing Botox regimens in patients with adductor spasmodic dysphonia and essential tremor of voice: A 31‐year experience
por: Stone, Amy, et al.
Publicado: (2022) -
Tridimensional assessment of adductor spasmodic dysphonia pre- and post-treatment with Botulinum toxin
por: Dejonckere, P. H., et al.
Publicado: (2011)